Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2005
03/31/2005US20050069522 Combination pharmaceutical agents as inhibitors of HCV replication
03/31/2005US20050069521 Enhancing the circulating half-life of interleukin-2 proteins
03/31/2005US20050069518 Mixture of nicotine polymer and vasodilator; promote angiogenesis; therapy for erectile dysfunction, cardiovascular disorders, strokes
03/31/2005DE10341518A1 Pharmazeutischer Wirkstoff gegen Hepatitis Pharmaceutical drug for hepatitis
03/31/2005DE10341307A1 Pharmarzeutischer Wirkstoff gegen Brustkrebs Pharmarzeutischer agent against breast cancer
03/31/2005DE10340260A1 Mittel und Verfahren zur Behandlung und Prävention von TSE, sowie Verfahren zur Herstellung des Mittels Compositions and methods for treatment and prevention of TSE, and to processes for the preparation of the agent
03/31/2005CA2540172A1 Liquid human growth hormone formulation containing polyethylene glycol
03/31/2005CA2540103A1 Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization
03/31/2005CA2539789A1 Peptide originating in hepatitis c virus
03/31/2005CA2539437A1 Peptide that binds to a broadly neutralizing anti-hiv antibody-structure of 4e10 fab fragment complex, uses thereof, compositions therefrom
03/31/2005CA2539364A1 Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome
03/31/2005CA2539357A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
03/31/2005CA2539322A1 Kid3 and kid3 antibodies that bind thereto
03/31/2005CA2539288A1 Thyroid hormone analogs and methods of use
03/31/2005CA2539253A1 Albumin-binding derivatives of therapeutic peptides
03/31/2005CA2539181A1 Modulation of eif4e expression
03/31/2005CA2539127A1 Receptor
03/31/2005CA2538999A1 Regulation of cardiac contractility and heart failure propensity
03/31/2005CA2538998A1 Large scale preparation of alpha-1 proteinase inhibitor and use thereof
03/31/2005CA2538846A1 Enhanced method of treatment of growth disorders
03/31/2005CA2538802A1 Treating or preventing restless legs syndrome using prodrugs of gaba analogs
03/31/2005CA2538791A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
03/31/2005CA2538284A1 Modulators of p-selectin glycoprotein ligand 1
03/31/2005CA2537989A1 Methods and reagents for the treatment of immunoinflammatory disorders
03/31/2005CA2532831A1 Host defense factor x (hdfx)
03/30/2005EP1519193A2 Methods for detecting cancers expressing vascular endothelial growth factor D
03/30/2005EP1518933A1 Vectors and methods for gene transfer to cells
03/30/2005EP1518930A2 Methods and compositions for inhibiting neoplastic cell growth
03/30/2005EP1518928A1 Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders relating to androgen metabolism, their pharmaceutical compositions, their uses and treatment method
03/30/2005EP1518863A1 Antibodies modulating the activity of equine chorionic gonadotropin.
03/30/2005EP1518557A1 Anti-hiv agent
03/30/2005EP1518553A2 Use of nitrate ester compounds for treating pain or providing analgesia
03/30/2005EP1518117A1 Method for diagnosing and treating nis-expressing carcinomas and metastases
03/30/2005EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
03/30/2005EP1517988A2 Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure
03/30/2005EP1517981A2 Stabilization of granules
03/30/2005EP1517923A2 Compositions and methods for inhibiting microbial adhesion
03/30/2005EP1517919A2 Marked peptides having affinity for a phospholipid and uses
03/30/2005EP1517918A2 Peptides having affinity for a phospholipid and uses
03/30/2005EP1517916A2 Peptides having antimicrobial properties and compositions containing same in particular for preserving foods
03/30/2005EP1517915A2 Prodrugs of excitatory amino acids
03/30/2005EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517892A1 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
03/30/2005EP1517724A2 Anti-angiogenic proteins and fragmentsand methods of use thereof
03/30/2005EP1517710A1 Pegylated factor vii glycoforms
03/30/2005EP1517705A1 Dichloroacetate in combination with cardioprotective or hemodynamic drugs
03/30/2005EP1517699A1 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
03/30/2005EP1517698A1 Stabilised solid compositions of factor vii polypeptides
03/30/2005EP1517697A1 Acidic insulin preparations with improved stability
03/30/2005EP1517696A1 Prevention, therapy and prognosis/monitoring in sepsis and septic shock
03/30/2005EP1517695A2 Osteopontin, oligodendrocytes and myelination
03/30/2005EP1517674A2 Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production
03/30/2005EP1517619A1 Satiety inducing composition
03/30/2005EP1517606A2 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
03/30/2005EP1429648A4 METHODS FOR SCREENING FOR SUBSTANCES WHICH INHIBIT FP PROSTANOID RECEPTOR INTERACTION WITH A COMPOUND HAVING PGF 2$g(a)alpha?ACTIVITY AND METHODS OF TREATING CANCER
03/30/2005EP1392341B1 Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof
03/30/2005EP1224298B1 Fibrinolytically active polypeptide
03/30/2005EP1200105B1 Modified factor viii
03/30/2005EP1185294B1 Peptides for the treatment of impaired interpersonal and behavioral disorders
03/30/2005EP1183361B1 Gene therapy of pulmonary disease
03/30/2005EP1181035B1 Substantially oil-free cyclosporin compositions
03/30/2005EP1135414B1 Allo and auto-reactive t-cell epitopes
03/30/2005EP1124570A4 Novel neuropilin/growth factor binding and uses thereof
03/30/2005EP1076561B1 Combination therapy for the treatment of tumors
03/30/2005EP1001978B1 Angiotensin derivatives
03/30/2005EP0928290B1 Oligoribonucleotides and ribonucleases for cleaving rna
03/30/2005EP0876610A4 A method and use of polypeptide in sperm-egg binding to enhance or decrease fertility
03/30/2005EP0838474B1 Peptide that inhibits blood triglyceride level rise and blood triglyceride level rise inhibitor containing said peptide as active ingredient
03/30/2005EP0791056B1 Lipid-cleavage enzyme complex
03/30/2005EP0585415B1 Dna encoding a human 5-ht 1e receptor and uses thereof
03/30/2005CN1602360A Methods of increasing endogenous erythropoietin (EPO)
03/30/2005CN1602358A Recombinant fusion proteins and the trimers thereof
03/30/2005CN1602355A Human fibroblast growth factor-related compositions
03/30/2005CN1602354A Human coagulation factor VII polypeptides
03/30/2005CN1602315A Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
03/30/2005CN1602203A Use of gp130 activators in diabetic neuropathy
03/30/2005CN1602201A Peptides and related compounds having thrombopoietic activity
03/30/2005CN1602200A Plant extract active as an immunostimulating agent
03/30/2005CN1602192A Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
03/30/2005CN1602186A Prolonged release biodegradable microspheres and method for preparing same
03/30/2005CN1600857A RIP5 gene and usage
03/30/2005CN1600854A New diatom manganese type superoxide dismutase and usage
03/30/2005CN1600792A Active material of polypeptide proteins in bloody clam, preparation method and usage
03/30/2005CN1600789A Promotive factor for activating NF-kappa B and usage
03/30/2005CN1600788A Distinguishing gene for adjusting and controlling anti-oncogene p53 and usage
03/30/2005CN1194990C Polypeptide motif bound with human CD95 and its polypeptide
03/30/2005CN1194988C Killer cell antibiosis polypeptide activated lymphokine and its application
03/30/2005CN1194987C Purified polypeptide with bioactiveity and medicine preparied from it for promoting growth and and development of animal's nerve cells and suppressing their apotosis
03/30/2005CN1194986C Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof
03/30/2005CN1194762C Gene therapy for cerebrovasclar disorders
03/30/2005CA2443423A1 Use of cardiotrophon-1 to promote wound healing and counteract overt fibrosis
03/29/2005US6872838 Derivatives of water insoluble drugs which exhibit good activity and water solubility
03/29/2005US6872811 HRPCa9 and HRPCa10 nucleic acids and polypeptides
03/29/2005US6872808 Nematode-extracted serine protease inhibitors and anticoagulant proteins
03/29/2005US6872805 Hepatitis C virus inhibitors
03/29/2005US6872750 Modulating angiogenesis
03/29/2005US6872745 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
03/29/2005US6872705 Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
03/29/2005US6872703 Insulin receptor-related receptor binding protein
1 ... 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 ... 3163